TFF Pharmaceuticals Inc. - Bathi saben saham sajroning taun lumaku TFFP

TFF Pharmaceuticals has developed a thin-film freezing method that converts injections into a convenient powder for inhalation. The year-over-year change in EPS (TTM) confirms the profit trend, with the latest figure standing at 53.20. Revenues are based on royalties from major corporations for the use of patents. The asset-light model ensures scalability through the sale of licenses without incurring costs for factories and logistics.
TFF Pharma - rincian analitis lan metrik utama (TFFP)

Fundamental risks for TFF Pharmaceuticals (TFFP) necessitate precise monitoring of profit dynamics. The specifics of biopharmaceuticals and the vulnerability of supply chains make financial stability critical. This year-over-year (TTM) EPS change captures the percentage shift in net income per share over the last 12 months relative to the previous year. The metric reveals the gap between financial reporting and market expectations. Extremes in year-over-year (TTM) EPS change signal the risk of overpaying for the asset.